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The  chemokine  receptor  CXCR4  is  a  widely 
expressed G protein-coupled receptor that has 
been  implicated  in  a  number  of  diseases 
including HIV, cancer, and WHIM syndrome, 
with the latter two involving dysregulation of 
CXCR4  signaling.  To  better  understand  the 
role of phosphorylation in regulating  CXCR4 
signaling,  tandem  mass  spectrometry  and 
phospho-specific  antibodies  were  used  to 
identify  sites  of  agonist-promoted 
phosphorylation.  These studies demonstrated 
that Ser-321, Ser-324, Ser-325, Ser-330, Ser-339 
and  two  sites  between  Ser-346-352  were 
phosphorylated  in  HEK293  cells.    We  show 
that Ser-324/5 was rapidly phosphorylated by 
protein  kinase  C  and  G  protein-coupled 
receptor  kinase  6  [GRK6]  upon  CXCL12 
treatment  while  Ser-339  was  specifically  and 
rapidly phosphorylated by GRK6. Ser-330 was 
also  phosphorylated  by  GRK6,  albeit  with 
slower kinetics.  Similar results were observed 
in  human  astroglia  cells,  where  endogenous 
CXCR4  was  rapidly  phosphorylated  on  Ser-
324/5 by protein  kinase  C  following  CXCL12 
treatment  while  Ser-330  was  slowly 
phosphorylated.  Analysis of CXCR4 signaling 
in  HEK293  cells  revealed  that  calcium 
mobilization  was  primarily  negatively 
regulated by GRK2, GRK6 and arrestin3 while 
GRK3, GRK6, and arrestin2 played a primary 
role in positively regulating ERK1/2 activation. 
In contrast, GRK2 appeared to play a negative 
role  in  ERK1/2  activation.  Finally,  we  show 
that  arrestin  association  with  CXCR4  is 
primarily driven by the phosphorylation of far 
C-terminal  residues  on  the  receptor.  These 
studies reveal that site-specific phosphorylation 
of CXCR4 is dynamically regulated by multiple 
kinases resulting in both positive and negative 
modulation of CXCR4 signaling.    
 
CXCR4  is  a  widely  expressed  chemokine 
receptor  that  is  essential  for  development, 
hematopoiesis, organogenesis, and vascularization 
(1).      CXCR4  also  plays  a  prominent  role  in  a 
number  of  diseases  including  WHIM  syndrome 
(2), HIV-1 entry (3) and cancer progression and 
metastasis (4).  Interestingly, WHIM syndrome is 
the  direct  result  of  C-terminal  truncations  of 
CXCR4 that result in enhanced receptor function 
(5).  CXCR4 is also overexpressed in at least 23 
different  types  of  cancer  (6)  and  accumulating 
evidence  suggests  that  there  is  dysregulation  of 
CXCR4  transcription,  signaling  and  trafficking 
(1). 
Protein phosphorylation is the most prevalent 
post-translational modification and plays a major 
role  in  regulating  protein  function  (7,  8).  
Importantly, phosphorylation is one of the earliest 
events  in  regulating  G  protein-coupled  receptor 
(GPCR) signaling, initiating a process known as 
desensitization  (9,  10).  Agonist-promoted 
desensitization is primarily mediated by members 
of  the  GPCR  kinase  (GRK)  family,  which 
specifically  phosphorylate  agonist-occupied 
GPCRs (9-11).  This promotes the recruitment and 
high affinity binding of arrestins, which function 
to  uncouple  the  receptor  from  G  protein,  target 
receptors  for  internalization,  and  promote  G 
protein-independent  signaling  (12,  13).    Studies 
with  the  prototypical  GPCR,  rhodopsin,  have 
shown  that  the  receptor  is  phosphorylated  on 
multiple residues in vitro and in vivo by GRK1 
(14,  15),  resulting  in  the  recruitment  of  visual 
arrestin  and  light  adaptation  (16).    Subsequent 
work  has  demonstrated  how  alterations  in  these 
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regulatory  mechanisms  have  direct 
pathophysiological consequences (17).  Germline 
mutations in either GRK1 or visual arrestin results 
in a lack of receptor desensitization and the onset 
of Oguchi’s disease (18, 19).  While the specific 
protein  kinases  that  mediate  phosphorylation  of 
other  GPCRs  have  not  been  well  defined,  site-
specific  and  tissue-specific  phosphorylation  of 
GPCRs  likely  have  distinct  effects  on  signaling 
(20).  
CXCR4  is  rapidly  phosphorylated  within  its 
45  amino  acid  serine/threonine-rich  C-terminal 
tail  upon  activation.    Previous  studies  have 
suggested a number of potential phosphorylation 
sites  critical  for  agonist  (CXCL12)-  and  PKC-
mediated  receptor  internalization  (21,  22)  and 
degradation (23).  In addition, GRK2 (22, 24, 25), 
GRK3  (26),  GRK6  (27,  28),  and  PKC  (22,  29) 
have  been  implicated  in  CXCR4  regulation, 
although the sites of phosphorylation, the kinases 
involved in the phosphorylation of specific sites, 
and  the  functional  role  of  site-specific 
phosphorylation remain largely unknown.  
 In  order  to  better  understand  the  role  of 
phosphorylation  in  regulating  CXCR4  function, 
we  sought  to  identify  agonist-promoted  sites  of 
phosphorylation and the kinases that mediate site-
specific  phosphorylation.    Using  liquid 
chromatography  tandem  mass  spectrometry 
[LC/MS/MS] and phospho-specific antibodies, we 
identified  seven  serine  residues  that  are 
phosphorylated  in  response  to  CXCL12 
stimulation.    We  show  that  phosphorylation  of 
these sites occurs with distinct kinetics and kinase 
specificity:  namely  Ser-324/5  phosphorylation  is 
rapid, transient and is primarily mediated by PKC 
and  GRK6;  Ser-330  phosphorylation  is  delayed 
and  is  mediated  by  GRK6;  and  Ser-339  is 
phosphorylated  rapidly  by  GRK6.    Finally,  we 
show  that  GRK-mediated  phosphorylation  of 
CXCR4 has distinct effects on arrestin recruitment 
and conformation leading to differential effects on 
calcium  mobilization  and  ERK1/2  activation 
following CXCR4 activation.  
 
EXPERIMENTAL PROCEDURES 
 
Cell  culture  and  transfections.    HEK293  cells 
(Microbix, Toronto, Canada) were maintained in 
complete  Dulbecco’s  modified  Eagle’s  medium 
(DMEM)  with  10%  fetal  bovine  serum  and  25 
mM  HEPES,  pH  7.4.    Cells  stably  expressing 
human CXCR4 were selected and maintained in 
complete  DMEM  supplemented  with  0.8  mg/ml 
G418 and penicillin/streptomycin. HEK293 cells 
were plated in fresh complete DMEM 24 hr prior 
to  RNAi  transfection.  Normal  human  astrocytes 
derived  from  neural  precursor  cells  were 
purchased from ScienCell Research Laboratories 
(San Diego, CA). Cells were cultured in Astrocyte 
Medium  supplemented  with  fetal  bovine  serum 
(2%) and Astrocyte Growth Supplement provided 
by the vendor. As previously reported (30), these 
cells express functional CXCR4 and maintain an 
astroglial  phenotype  during  the  entire  culture 
period,  as  assessed  by  glial  fibrillary  acidic 
protein staining. Cells were used for 2-3 passages 
and serum starved for 24 hr before experimental 
treatments.  All  siRNAs  were  synthesized  by 
Dharmacon  (Lafayette,  CO)  with  the  ON-
TARGET  plus  modification.    Four  separate 
siRNAs were reconstituted and pooled at a final 
concentration of 15 pmol/µl.  GRKs were targeted 
against the following sense strands:  GRK2 – 5’ 
GGGACGUGUUCCAGAAAUU  3’;  5’ 
GCUCGCAUCCCUUCUCGAA  3’;  5’ 
GGAAUCAAGUUACUGGACA  3’;  5’ 
GCAAUAAGUUCACACGGUU  3’;  GRK3  –  5’ 
GGAGUGUGAUGCAGAAGUA  3’;  5’ 
GAGGAUACCAAAGGGAUUA  3’;  5’ 
GGGAAGGACUGUAUUAUGC  3’;  5’ 
GAACACGUACAAAGUCAUU  3’;  GRK5  – 
5’CCAACACGGUCUUGCUGAA  3’;  5’ 
GGGAGAACCAUUCCACGAA  3’; 
CAAACCAUGUCAGCUCGAA  3’;  5’ 
GAUUAUGGCCACAUUAGGAUU  3’;  GRK6  – 
5’GGUGAAGAAUGAACGGUAC  3’;  5’ 
GAGCUUGGCCUACGCCUAU  3’; 
GCACGUAACGCAGAAUUUU  3’;  5’ 
CGCCAAGAUUGCUGUGGAA  3’.    PKCδ  was 
targeted  against  the  following  sense  strands:  5’ 
CCAUGAGUUUAUCGCCACC  3’;  5’ 
CAGCACAGAGCGUGGGAAA  3’.  The  arrestin 
and  PKCα  siRNAs  have  been  previously 
described  (31,  32).    The  PKC  siRNAs  were 
reconstituted individually at 60 pmol/µl. Prior to 
transfection, 300 pmol of each were combined for 
a  total  of  600  pmol/transfection.    Non-targeting 
siRNA  pooled  control  modified  with  the  ON-
TARGET  plus  modification  was  used  as  the 
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control in all siRNA experiments. HEK293 cells, 
~65 to 70% confluent, were transfected with 600 
pmol  of  siRNA  using  Lipofectamine  2000 
(Invitrogen)  in  OPTI-MEM  (Invitrogen)  per  the 
manufacturer’s  instructions.    Cells  were 
maintained in low-serum media for 4 hr, at which 
point  an  equal  volume  of  2X  complete  media 
(20% FBS and 25 mM HEPES) was added.  Cells 
were  split  48  hr  post-transfection  for  assay  the 
following day.   
Site-specific  mutagenesis  was  carried  out 
using the Quick change site directed mutagenesis 
kit (Stratagene) per the manufacturer’s guidelines.  
All mutations were verified by sequencing. 
 
Purification of Flag CXCR4.  Purification of Flag-
tagged  CXCR4  was  performed  as  previously 
described  for  the  β2-adrenergic  receptor  (β2AR) 
(33)  with  minor  modifications.    Cells  grown  to 
~90%  confluency  in  five  15-cm  plates  were 
washed  twice  with  phosphate  buffered  saline 
(PBS).  Cells were then incubated in serum free 
DMEM  for  6  hr,  the  media  was  aspirated,  and 
replaced with fresh serum free DMEM containing 
50 nM CXCL12 for 10 min.  Cells were scrapped 
into 10 ml of hypotonic lysis buffer (20 mM Tris-
HCl, pH 7.5, 2.5 mM CaCl2, 10 mM NaF, and one 
Complete  Protease  inhibitor  tablet  (EDTA-free)) 
and lysed by 10 strokes in a Dounce homogenizer 
(tight  pestle).    Membranes  were  pelleted  by 
centrifugation at 40,000 x g for 20  min at 4°C.  
Pellets were resuspended in 10 ml of Buffer A (20 
mM  Tris-HCl,  pH  7.5,  100  mM  NaCl,  10  mM 
NaF,  1%  dodecyl  maltoside  (DDM),  2.5  mM 
CaCl2, and one Complete protease inhibitor tablet 
(EDTA-free)) and homogenized by 20 strokes in a 
Dounce homogenizer.  Cellular debris was cleared 
by centrifugation at 40,000 x g for 20 min at 4°C.  
The resulting supernatant was passed over an M1 
anti-flag affinity (Sigma-Aldrich, St Louis, MO) 
column (0.4 ml resin/10 ml of lysate, flow rate of 
5 ml/hr) equilibrated in Buffer  B (20  mM  Tris-
HCl, pH 7.5, 150 mM NaCl, 0.1% DDM, 2.5 mM 
CaCl2)  at  room  temperature.    The  column  was 
washed once with 5 ml of Buffer C (20 mM Tris-
HCl, pH 7.5, 300 mM NaCl, 0.1% DDM, 2.5 mM 
CaCl2)  at  a  rate  of  10  ml/hr  followed  by  an 
additional wash with 5 ml of Buffer  B.  Bound 
receptor  was  then  eluted  from  the  column  in 
Buffer  D  (20  mM  Tris-HCl,  pH  7.5,  150  mM 
NaCl, 0.1% DDM, 200 µM Flag peptide, 1 µM 
AMD 3100, 10 mM EDTA) in 1 ml fractions and 
immediately  snap  frozen  in  liquid  nitrogen  and 
stored at –80°C. Fractions containing CXCR4 (by 
Western blot) were concentrated using Microcon 
ultracell  YM-10  concentrators  (Millipore 
Cooperation,  Billerica,  MA).  Purified  CXCR4 
was  electrophoresed  on  a  4-20%  SDS-Glycine 
gradient  gel  (Invitrogen,  Carlsbad  CA),  stained 
with  Coomassie  blue,  de-stained,  excised  and 
shipped  on  ice  to  the  University  of  Virginia 
Biomedical  Research  Facility  for  LC/MS/MS 
analysis.  
 
LC/MS/MS procedure. Gel pieces were transferred 
to  siliconized  tubes,  washed  and  destained 
overnight in 200 µl of 50% methanol.   The gel 
pieces  were  dehydrated  in  acetonitrile  and  then 
rehydrated in 30 µl of 10 mM dithiothreitol in 0.1 
M ammonium bicarbonate and incubated at room 
temperature  for  30  min.    The  solution  was 
removed and the sample was alkylated in 30 µl of 
50  mM  iodoacetamide  in  0.1  M  ammonium 
bicarbonate at room temperature for 30 min.  The 
gel  pieces  were  dehydrated  in  100  µl  of 
acetonitrile,  rehydrated  in  100  µl  of  0.1  M 
ammonium bicarbonate, dehydrated in 100 µl of 
acetonitrile,  completely  dried  by  vacuum 
centrifugation and then rehydrated in 20 µl of 50 
mM ammonium bicarbonate containing 20 ng/µl 
Lys-C or chymotrypsin and incubated overnight at 
37
oC.  Peptides  were  extracted  from  the 
polyacrylamide  in  two  30  µl  aliquots  of  50% 
acetonitrile/5% formic acid and the extracts were 
combined  and  evaporated  to  15  µl  for  mass 
spectrometry analysis.   
The  LC/MS  system  consisted  of  a  Thermo 
Electron LTQ-FT mass spectrometer system with 
a  Protana  nanospray  ion  source  interfaced  to  a 
self-packed 8 cm x 75 µm id Phenomenex Jupiter 
10  µm  C18  reversed-phase  capillary  column. 
Extract (1-5 µl) was injected and peptides eluted 
from the column using an acetonitrile/0.1 M acetic 
acid gradient at a flow rate of 0.25 µl/min.  The 
nanospray ion source was operated at 2.8 kV.  The 
digest  was  analyzed  using  the  double  play 
capability  of  the  instrument  acquiring  full  scan 
mass  spectra  (ion  cyclotron  resonance;  100K 
resolution)  to  determine  peptide  molecular 
weights and five product ion spectra (ion trap) to 
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determine  amino  acid  sequence  in  sequential 
scans.    This  mode  of  analysis  produces 
approximately  1500  collision  activated 
dissociation spectra of ions ranging in abundance 
over several orders of magnitude.  The data were 
analyzed by database searching using the Sequest 
search  algorithm  against  CXCR4.  Putative 
phosphorylated  peptides  were  confirmed  by 
manual analysis. 
 
Generation  of  polyclonal  antibodies  specific  for 
pS324/5 and pS330. Polyclonal antibodies specific 
for pS324/5 and pS330 were generated by Open 
Biosystems  (Huntsville,  AL).    Briefly,  peptides 
corresponding to phosphorylated CXCR4 at Ser-
324/5  (C-Ahx-RG(pS)(pS)LKIL  where  Ahx  is 
amino  hexonic  acid)  and  Ser-330 
(CLKIL(pS)KGKRGGH)  were  synthesized, 
coupled  to  hemocyanin  and  used  to  immunize 
rabbits  following  a  standard  immunization 
protocol.    Crude  sera  from  each  rabbit  was 
collected at days 28, 56 and 72 following primary 
immunization  and  tested  for  immuno-reactivity.  
Antibody  was  purified  from  pooled  bulk  sera 
(days 56 and 72) from animal  E5199 (pS324/5) 
and E5198 (pS330) using the immunizing peptide, 
concentrated to 1 mg/ml, and aliquots were stored 
at –80°C.  Antibody specificity was evaluated by 
preincubating  10  µg  of  purified  antibody  with 
vehicle (PBS), 10 µg of the immunizing peptide 
or 10 µg of the non-phosphorylated peptide. 
 
Calcium  mobilization  and  ERK1/2  activation.  
Calcium  mobilization  was  performed  as 
previously described (31).  For analyzing ERK1/2 
activation, cells were plated into 6-well plates 24 
hr  prior  to  stimulation.    Confluent  cells  were 
washed twice with PBS and maintained in 1 ml of 
serum  free  DMEM  for  6  hr  at  37°C  prior  to 
stimulation.    Following  stimulation,  media  was 
aspirated  on  ice  and  cells  were  lysed  by  the 
addition of 300 µl of 2x SDS sample buffer and 
stored  at  –80°C  until  processed.    Lysates  were 
thawed  on  ice,  sonicated  for  10  sec  (10% 
amplitude) and allowed to sit at room temperature 
for  30  min  prior  to  electrophoresis.    Equal 
volumes  were  separated  by  10%  SDS-PAGE, 
transferred  to  nitrocellulose,  blocked  with 
ODYSSEY
  blocking  buffer  (Li-Cor
 
Biosciences) and blotted overnight with a mixture 
of  anti-phospho-p42/44  (Cell  Signaling 
Technologies, Boston, MA) and anti-ERK2 (Santa 
Cruz, Santa Cruz, CA).  The following day, blots 
were washed extensively with Tris buffered saline 
containing  0.1%  Tween-20  (TBS-T),  incubated 
with  a  mixture  of  goat  anti-rabbit  Alexa
 
Fluorophore  680  conjugated  (Molecular  Probes) 
and  goat  anti-mouse  IRDye  800  conjugated 
secondary  (Rockland  Immunochemicals) 
antibodies (1:5000) for 1 hr at room temperature.  
Blots were  washed extensively  with  TBS-T and 
visualized using the ODYSSEY
 infrared imaging 
system (Li-Cor
 Biosciences). 
 
Detection of pS324/5, pS330 and pS339.  HEK293 
cells  stably  expressing  Flag  CXCR4  were 
stimulated and processed as described for ERK1/2 
activation.  An equal volume of cell lysate (Flag 
CXCR4) or 20 µg of whole cell extract (astroglia) 
was separated by 10% SDS-PAGE, transferred to 
nitrocellulose  and  blocked  for  1  hr  in  0.25% 
gelatin.    Blots  were  incubated  overnight  at  4°C 
with a  mixture of anti-CXCR4 (BD Bioscience) 
and  anti-pS324/5,  anti-pS330,  or  anti-pS339 
primary  antibodies.    Blots  were  extensively 
washed with TBS-T and incubated with a mixture 
of  goat  anti-rabbit  Alexa
  Fluorophore  680 
conjugated  (Molecular  Probes)  and  goat  anti-rat 
IRDye  800  conjugated  secondary  (Rockland 
Immunochemicals)  antibodies  for  1  hr  at  room 
temperature.  Blots  were  developed  as  described 
above for phospho-ERK.   Phospho-CXCR4  was 
then normalized to total CXCR4 and represented 
as  percent  maximum.    For  assays  with  PKC 
inhibition,  cells  were  pretreated  with  vehicle 
(DMSO) or appropriate inhibitor for 30 min prior 
to stimulation with CXCL12. 
 
Electrophoretic  mobility  shift  assay.    An  equal 
volume of cell lysate was separated by 10% SDS-
PAGE for 1 hr 40 min at ~135V, transferred to 
nitrocellulose and blocked for 1 hr in 5% milk in 
TBS-T.    Blots  were  subsequently  probed  for 
CXCR4 as described above for phospho-CXCR4. 
 
Bioluminescence  resonance  energy  transfer 
(BRET) assay. For BRET studies, HEK293T cells 
were  maintained  in  DMEM  supplemented  with 
5% fetal bovine serum, 100 units/ml penicillin and 
streptomycin,  all  from  Wisent.    Twenty  four  hr 
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before transfection, cells were seeded at a density 
of  500,000  cells  per  well  in  6-well  dishes. 
Transient transfections were performed using the 
linear  polyethylenimine  (Mw  25000, 
Polysciences,  Warrington,  PA)  method  with  a 
DNA: polyethylenimine ratio of 2:7. Twenty ng of 
CXCR4-RLucII,  120  ng  of  GRK6SA  CXCR4-
RLucII, or 90 ng of 5Atail CXCR4-RLucII were 
co-transfected  with  either  500  ng  of  GFP2-
arrestin2 or GFP2-arrestin3. The total amount of 
DNA transfected in each well was adjusted to 2 
µg  with  salmon  sperm  DNA.  After  overnight 
incubation,  transfection  medium  was  replaced 
with fresh DMEM for 3 hr to allow cell recovery. 
Transfected  cells  were  then  detached,  seeded  in 
pre-treated  poly-L-ornithine  hydrobromide 
(Sigma  Aldrich,  P3655)  96-well  white  plates  at 
100,000 cells per well and left in culture for an 
additional 24 hr before being processed for BRET 
assay. 
  The  expression  level  of  the  energy  acceptor 
(GFP2)  tagged  proteins  was  measured  as  total 
fluorescence  using  a  FlexStationII  (Molecular 
Device) with an excitation filter at 395 nm and an 
emission filter at 510 nm. The expression level of 
the  energy  donor  (RLucII)  tagged  protein  was 
measured  using  a  Mithras  LB940  multidetector 
plate  reader
  (Berthold  Technologies,  Bad 
Wildbad,  Germany)  in  the  presence  of  5  µM 
coelenterazine  400A  (Biotium,  Hayward,  CA) 
after 5 min incubation. 
For BRET measurements, cells were washed 
once 36 to 48 hr after transfection with PBS and 
coelenterazine  400A  was  added  to  a  final 
concentration  of  5  µM  in  PBS  5  min  before 
reading.  Readings  were  then  collected  using  a 
MITHRAS  LB940  multidetector  plate  reader 
allowing the sequential integration of the signals 
detected in the 480 (±) 20 nm and 530 (±) 20 nm 
windows for luciferase and GFP2 light emissions, 
respectively. The BRET signal was determined by 
calculating the ratio of the light intensity emitted 
by  the  GFP2-arrestin  over  the  light  intensity 
emitted by the Receptor-RLucII. The values were 
corrected  by  subtracting  the  background  BRET 
signal  detected  when  the  Receptor-RLucII 
construct  was  expressed  alone.  To  assess  the 
effects of ligand, CXCL12 was added at 100 nM 
just before reading. 
 
Statistical Analysis.  All data are represented as 
the mean ± standard error of the mean (S.E.M.).   
Data were analyzed using a two-tailed student’s t-
test with significance set at p≤0.05. 
 
RESULTS 
 
Phospho-site  mapping  of  CXCR4  by  mass 
spectrometry.  CXCR4 is rapidly phosphorylated 
and internalized following agonist-activation (22, 
29,  34).    Truncation  of  the  C-terminal  tail  of 
CXCR4, which contains 15 serine and 3 threonine 
residues,  eliminates  agonist-promoted 
phosphorylation,  attenuates  internalization,  and 
enhances receptor activity (29, 34).  Since alanine 
scanning  mutagenesis  suggested  that  multiple 
regions  of  the  C-tail  may  be  phosphorylated 
following  CXCL12  stimulation  (22),  we  used 
mass  spectrometry  to  better  define  the  specific 
sites  phosphorylated  in  CXCR4.  We  initially 
made  a  cell  line  stably  expressing  Flag-tagged 
CXCR4  to  enable  rapid  purification  of  the 
receptor, as previously demonstrated for the β2AR 
(33).  HEK293 cells were chosen as a model cell 
because  they  express  CXCR4  endogenously, 
though  at  very  low  levels  (~20  fmol/mg 
membrane protein).  A clonally selected HEK293 
cell line expressing Flag-tagged CXCR4 at ~0.5 
pmol/mg (termed Flag CXCR4 cells) was chosen 
for  further  study.    CXCL12  stimulation  of 
endogenous CXCR4 in HEK293 cells resulted in 
robust  calcium  mobilization  (Fig.  1A)  and 
ERK1/2 activation (Fig. 1B), although due to low 
expression  of  endogenous  CXCR4,  we  were 
unable to detect CXCL12-mediated inhibition of 
cAMP  production  or  activation  of  p38  or  AKT 
(data not shown).   Stable-expression of  CXCR4 
did  not  enhance  CXCL12-mediated  calcium 
mobilization (Figure 1A) but did lead to an ~2.5 
fold increase in activation of ERK1/2 (Fig. 1B).  
In  addition,  as  an  indirect  measure  of  receptor 
phosphorylation,  we  looked  at  the  ability  of 
CXCL12  to  induce  an  electrophoretic  mobility 
shift of CXCR4 on SDS-PAGE.  Stimulation of 
either  HEK293  cells  (Fig.  1C)  or  Flag  CXCR4 
cells (Fig. 1D) resulted in a rapid retardation of 
electrophoretic mobility, consistent with receptor 
phosphorylation.    Thus,  the  Flag  CXCR4  cells 
appear to be a good model to further characterize 
CXCR4 phosphorylation. 
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Mass  spectrometry  has  become  a  valuable 
tool  for  identifying  amino  acids  that  are  post-
translationally modified (35),  a strategy  recently 
employed  for  the  β2AR  (33).    Since 
phosphorylation  adds  ~80  daltons  (Da)  to  the 
molecular  mass  of  a  peptide,  peptides  with 
changes of 80 Da (or multiples thereof) from the 
theoretical  mass  can  be  identified,  trapped  and 
subsequently  fragmented  by  MS/MS  to  provide 
site-specific information on phosphorylation (35).  
To identify sites of phosphorylation on CXCR4, 
Flag CXCR4 cells were treated with CXCL12 for 
10 min and the receptor was then affinity purified 
on an anti-Flag column (Fig. 2A). This procedure 
resulted  in  ~80%  recovery  of  the  receptor  and 
yielded  ~0.5  µg  of  purified  CXCR4  per 
preparation  (Fig.  2B).    Duplicate  samples  of 
purified  CXCR4  were  then  digested  with  either 
Lys-C or chymotrypsin and the resulting peptides 
were  subjected  to  LC/MS/MS.    This  identified 
peptides  containing  38  of  the  45  C-terminal 
residues  of  CXCR4  including  residues  310-328 
and  334-352,  and  several  of  the  peptides  were 
phosphorylated  (Table  1).    Fig.  2C  shows  a 
representative  mass  spectrum  of  a  peptide  (Thr-
318  to  Leu-328)  obtained  from  a  chymotryptic 
digest,  which  contains  five  potential 
phosphorylation sites (Thr-318, Ser-319, Ser-321, 
Ser-324, and Ser-325).  The peak occurring with a 
mass ratio of ~600 demonstrates that this peptide 
has two phosphates attached (M-(H3PO4)2).  The 
loss  of  phosphates  upon  fragmentation  was 
apparent when Ser-324 and Ser-325 were present 
in the fragment (see peaks b9-(H3PO4)2 and [b10-
(H3PO4)2]
2+) but not in a peptide containing Thr-
318,  Ser-319  and  Ser-321  (peak  b4), 
demonstrating that both Ser-324 and Ser-325 are 
phosphorylated.    These  results  were  confirmed 
from  two  separate  experiments  as  well  as  with 
peptides derived from Lys-C digestion (Table 1).  
Since  peptides  containing  Ser-325 
phosphorylation  alone  were  also  observed,  we 
speculate  that  Ser-325  is  phosphorylated  before 
Ser-324  although  we  were  unable  to  generate  a 
pS325-specific  antibody  to  directly  test  this.  
Overall,  these  studies  identified  six  sites  of 
phosphorylation  following  a  10  min  stimulation 
with  CXCL12:  Ser-321,  Ser-324,  Ser-325,  one 
residue from Ser-338 to Ser-341, one residue from 
Ser-346 to Ser-348, and either Ser-351 or Ser-352 
(Fig. 2D).  The specific sites of phosphorylation 
that occur from Ser-338 to Ser-352 were not able 
to be specifically determined by LC/MS/MS due 
to the serine-rich nature of this region.   
 
Protein  kinase  C  is  primarily  responsible  for 
phosphorylation  of  Ser-324/5.    Previous 
mutagenesis studies have identified Ser-324/5 as 
critical for CXCL12-induced internalization (22) 
and  degradation  (23)  as  well  as  PMA-promoted 
internalization  (22,  29).    To  further  characterize 
Ser-324/5  phosphorylation,  we  generated  a 
phospho-specific antibody to evaluate the kinetics 
of  phosphorylation  and  kinase-specificity  for 
these  residues.    A  10  min  stimulation  with 
CXCL12  resulted  in  robust  phosphorylation  of 
Ser-324/5 that was blocked by pre-incubation with 
the  immunizing  phospho-peptide  but  not  with 
vehicle  or  unphosphorylated  peptide  (Fig.  3A).  
Flag  CXCR4  cells  were  then  stimulated  for 
various times with CXCL12 and cell lysates were 
electrophoresed and blotted with anti-pS324/5 to 
assess  the  kinetics  of  phosphorylation. 
Phosphorylation  of  Ser-324/5  rapidly  increased 
peaking at ~4-fold over basal within 5-10 min and 
returned to near basal levels within 60 min (Fig. 
3B).    Furthermore,  the  increase  in  pS324/5 
immuno-reactivity  paralleled  the  observed 
reduction  in  electrophoretic  mobility  of  CXCR4 
following  stimulation  with  CXCL12  (Figs.  1D 
and 3B). 
  CXCR4,  like  other  chemokine  receptors, 
primarily  couples  to  the  Gi  family  of 
heterotrimeric  G  proteins  (1).    In  order  to 
determine if G protein activation was involved in 
receptor  phosphorylation,  cells  were  pretreated 
with pertussis toxin prior to CXCL12 stimulation. 
Pertussis  toxin  pretreatment  significantly 
attenuated both the rate and extent of Ser-324/5 
phosphorylation  (Fig.  3C).    This  suggests  the 
possibility  that  activation  of  second  messenger 
dependent kinases such as PKC may contribute to 
phosphorylation  of  these  residues.    Indeed,  the 
primary amino acid sequence of CXCR4 reveals 
that both Ser-324 and Ser-325 fall within a PKC 
consensus motif (RGSSLK).  To initially address 
the  potential  role  of  PKC  in  agonist-promoted 
phosphorylation  of  Ser-324/5,  cells  were 
pretreated with the broad-spectrum PKC inhibitor 
Bisindolylmaleimide  I  (Bis  I)  or  the  negative 
control Bisindolylmaleimide V (Bis V) (36) prior 
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to CXCL12 stimulation.  Bis I treatment led to a 
significant reduction in basal phosphorylation as 
well  as  CXCL12-promoted  phosphorylation  of 
Ser-324/5 in HEK293 cells (Fig. 3D). 
  Since  Bis  I  inhibits  conventional  and  novel 
PKC isoforms, we attempted to better define the 
PKC  subtype(s)  involved  in  Ser-324/5 
phosphorylation  by  pretreating  cells  with  either 
Gö  6976,  which  inhibits  the  conventional  PKC 
isoforms (α, βI, and βII) (37) or rottlerin, which is 
reported  to  inhibit  PKCδ  (38).    Treatment  with 
rottlerin, but not with Gö 6976, led to a significant 
reduction  of  Ser-324/5  phosphorylation 
(supplemental  Fig.  S1A).    However,  since 
rottlerin  can  have  off-target  effects  (39),  we 
attempted to confirm the role of PKCδ in CXCR4 
phosphorylation  using  siRNA  treatment.    PKCδ 
levels  could  be  effectively  reduced  in  Flag 
CXCR4  cells  by  siRNA  treatment  and  this 
resulted  in  a  partial  decrease  in  Ser-324/5 
phosphorylation,  although  the  effect  was  not 
statistically  significant  (supplemental  Fig.  S1B). 
In contrast, knock down of PKCα had no effect 
on Ser-324/5 phosphorylation (supplemental Fig. 
S1B).  Taken together, these data demonstrate that 
PKC plays a major role in phosphorylating Ser-
324/5  following  CXCL12  stimulation.    The 
significant  effect  of  Bis  I  pretreatment  coupled 
with  the  fact  that  knock  down  of  PKCδ  only 
partially decreased phosphorylation, suggests that 
multiple  PKC  isoforms  likely  mediate  CXCR4 
phosphorylation.  
 
GRK6 contributes to Ser-324/5 phosphorylation.  
Since some phosphorylation of Ser-324/5 was still 
evident  following  pertussis  toxin  treatment  or 
PKC inhibition, we hypothesized that GRKs also 
contribute  to  phosphorylation  of  these  residues.  
The  GRKs  consist  of  seven  members,  four  of 
which  (GRK2,  3,  5,  and  6)  are  expressed  in 
HEK293  cells  (31,  40).    Since  there  are  no 
specific GRK inhibitors available, we assessed the 
effect  of  individual  GRK  knock  down  on  Ser-
324/5  phosphorylation.    While  efficient  and 
specific  knock  down  of  each  of  the  individual 
GRKs expressed in HEK293 cells was achieved 
(Fig.  4A),  only  GRK6  knock  down  had  a 
significant  effect  on  Ser-324/5  phosphorylation 
(Fig.  4B).    Since  our  results  suggest  that  both 
GRK6  and  PKC  contribute  to  Ser-324/5 
phosphorylation, we also evaluated the effect of 
PKC inhibition and GRK6 knock down.   While 
PKC  inhibition  or  GRK6  knock  down  alone 
resulted  in  an  ~50%  and  ~40%  reduction  in 
phosphorylation,  respectively,  the  combination 
resulted in an almost complete loss of Ser-324/5 
phosphorylation  (Fig.  4C).    These  data 
demonstrate that both PKC and GRK6 are needed 
for maximal agonist-promoted phosphorylation of 
Ser-324/5 following CXCL12 stimulation.  
 
Ser-330  and  Ser-339  are  phosphorylated  by 
GRK6.    Previous  studies  have  demonstrated  a 
prominent role of Ser-330 in regulating CXCL12-
promoted  degradation  (23)  while  Ser-339 
contributes  to  receptor  internalization  (21,  22).  
Although  a  peptide  containing  Ser-330  was  not 
observed  in  our  mass  spectrometry  analysis,  we 
generated  and  characterized  a  phospho-specific 
antibody  to  this  site.    In  addition,  a  phospho-
specific antibody has been generated against Ser-
339 (41) and phosphorylation within this region 
was also detected by mass spectrometry (Fig. 2D).   
As shown in Fig. 5A, both Ser-330 and Ser-339 
undergo agonist-promoted phosphorylation, albeit 
with different kinetics.   Phosphorylation of Ser-
330  was  relatively  slow  peaking  at  ~20  min, 
whereas  phosphorylation  of  Ser-339  was  very 
rapid peaking at ~2 min (Fig. 5A).  Interestingly, 
despite the kinetic differences, we found that both 
Ser-330  and  Ser-339  were  primarily 
phosphorylated by GRK6 (Figs. 5B and C).   
Overall, we found that GRK6 phosphorylates 
multiple  sites  including  Ser-324/5,  Ser-330  and 
Ser-339 while GRK2, 3, and 5 do not contribute 
to  CXCR4  phosphorylation  at  these  sites.  
Additional  studies  demonstrate  that  PKC 
inhibition  had  no  effect  on  CXCL12-promoted 
phosphorylation  of  Ser-330  and  Ser-339  in 
HEK293  cells  (data  not  shown),  demonstrating 
that  phosphorylation  of  these  residues  is 
completely  GRK6-dependent  in  response  to 
CXCL12. 
 
Protein  kinase  C  mediates  Ser-324/5 
phosphorylation in human astrocytes.  To further 
validate  Ser-324/5  and  Ser-330  as 
phosphorylation  sites,  we  also  examined  human 
astroglia,  normal  primary  cells  that  express 
CXCR4 endogenously (30).  Ser-324/5 was found 
to be rapidly phosphorylated following CXCL12 
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treatment  and  PKC  inhibition  effectively 
attenuated  phosphorylation  (supplemental  Fig. 
S2A).  Ser-330  was  also  phosphorylated  in 
astroglia, albeit more slowly. Interestingly, PKC 
inhibition  significantly  enhanced  the  basal 
phosphorylation  of  Ser-330  and  eliminated 
agonist-promoted  phosphorylation  (supplemental 
Fig.  S2B).  These  results  suggest  that  PKC  may 
negatively  regulate  the  basal  phosphorylation  of 
Ser-330,  possibly  by  regulating  the  activity  of 
another  protein  kinase  or  a  phosphatase.  Taken 
together,  these  studies  demonstrate  that  the 
kinetics  of  CXCR4  phosphorylation  in  HEK293 
and astroglia are comparable and that PKC plays a 
major  role  in  the  agonist-dependent 
phosphorylation of Ser-324/5. 
 
GRKs differentially regulate CXCR4 signaling in 
HEK293 cells. Phosphorylation of GPCRs is one 
of the earliest mechanisms of regulation, initiating 
the process of desensitization (9). Recent evidence 
suggests  that  differential  phosphorylation  of 
GPCRs can have specific but disparate effects on 
receptor regulation (30, 40, 42, 43). Since CXCR4 
activation  in  HEK293  cells  leads  to  calcium 
mobilization (Fig. 1A) and activation of ERK1/2 
(Fig. 1B), we next evaluated the functional role of 
GRKs  in  regulating  CXCR4-mediated  signaling.  
Knock down of GRK2 or GRK6, but not GRK3 or 
GRK5,  led  to  a  significant increase  in  the  peak 
calcium  transient  observed  following  CXCL12 
stimulation  of  endogenous  CXCR4  in  HEK293 
cells  (Fig.  6A).    Interestingly,  knock  down  of 
GRK2  led  to  an  ~30%  increase  in  ERK1/2 
activation while knock down of GRK3 or GRK6 
led  to  an  ~40%  reduction  in  ERK1/2  activation 
(Figs.  6B  and  C).    In  contrast,  knock  down  of 
GRK5  (Fig.  6C)  or  inhibition  of  PKC  by  Bis  I 
(data not shown) had no  effect on activation of 
ERK1/2 following CXCL12 activation.  
We  also  evaluated  whether  the  stable  over-
expression  of  CXCR4  altered  GRK-mediated 
regulation.  Similar to endogenous CXCR4, knock 
down  of  either  GRK2  or  GRK6  in  the  Flag 
CXCR4  cells  enhanced  calcium  mobilization, 
although GRK6 had a larger effect (supplemental 
Fig.  S3A).    Similarly,  knock  down  of  GRK2 
enhanced while knock down of GRK3 or GRK6 
decreased  activation  of  ERK1/2  (supplemental 
Fig. S3B and C).  Thus, stable over-expression of 
CXCR4  in  HEK293  cells  did  not  alter  the 
signaling  or  regulation  of  CXCR4.    Our  data 
suggest that phosphorylation of CXCR4 by GRK6 
and possibly GRK2 uncouples the receptor from 
activation of Gi, decreasing calcium mobilization.  
In  contrast,  GRK3  and  GRK6-mediated 
phosphorylation  of  CXCR4  positively  regulates 
activation of ERK1/2.  
 
Arrestins  differentially  regulate  signaling 
following CXCR4 activation.  Agonist-dependent 
phosphorylation  of  many  GPCRs  leads  to  the 
recruitment  of  the  non-visual  arrestins,  arrestin2 
and  arrestin3  (also  termed  β-arrestin1  and  β-
arrestin2, respectively). This effectively uncouples 
the  receptor  from  heterotrimeric  G  proteins, 
targets  the  receptor  for  internalization,  and 
nucleates G protein-independent signaling events 
(12, 13). Therefore, we next examined the effect 
of siRNA-mediated knock down of arrestin2 and 
3 on CXCR4 signaling in HEK293 cells.  Knock 
down  of  arrestin3  led  to  a  significant  increase, 
whereas arrestin 2 had only a modest effect, in the 
peak  calcium  transient  observed  following 
CXCL12 stimulation of endogenous (Fig. 7A) or 
overexpressed  (Fig.  7B)  CXCR4.    Conversely, 
knock  down  of  arrestin2  led  to  a  significant 
reduction  in  ERK1/2  activation  following 
CXCL12 stimulation of endogenous (Fig. 7C) or 
overexpressed  (Fig.  7D)  CXCR4,  while  knock 
down of arrestin3 had lesser effects. These results 
reveal that both arrestins contribute to regulating 
CXCR4  signaling  although  arrestin3  appears  to 
play the primary role in desensitization of calcium 
mobilization  while  arrestin2  plays  the  primary 
role in activation of ERK1/2 signaling. 
 
Site-specific  phosphorylation  of  CXCR4 
differentially regulates arrestin recruitment.  The 
observed  decrease  in  ERK  activation  following 
GRK3  or  GRK6  knock  down  could  arise  from 
either  the  inability  to  form  a  stable  CXCR4-
arrestin2  complex  (44,  45)  or  an  altered 
conformation of arrestin2 (40, 42) that does not 
allow  for  full  activation  of  ERK1/2.  To 
distinguish between these possibilities and further 
delineate  the  functional  role  of  site-specific 
phosphorylation  of  CXCR4  in  arrestin  binding, 
we performed bioluminescence resonance energy 
transfer studies between luciferase-tagged CXCR4 
and GFP-tagged arrestin2 and 3.   
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CXCL12  stimulation  resulted  in  a  time-
dependent  increase  in  the  BRET  ratio  observed 
between  CXCR4  and  arrestin2  (Fig.  8A)  or 
arrestin3 (Fig. 8B). Interestingly, slightly different 
kinetics  were  observed  for  the  two  arrestins, 
arrestin3  being  recruited  more  rapidly  than 
arrestin2.  Mutation of the last five serine residues 
in CXCR4 (5A Tail), to mimic loss of GRK2/3-
mediated  phosphorylation,  nearly  abolished  the 
recruitment  of  arrestin2  (Fig.  8C)  and  arrestin3 
(Figure  8D)  suggesting  that  phosphorylation  of 
the extreme C-terminus of the receptor is needed 
for  arrestin  recruitment.      In  striking  contrast, 
mutation  of  the  GRK6  phosphorylation  sites  in 
CXCR4  (Ser324/5,  Ser330,  and  Ser339; 
GRK6SA) resulted in an apparent increase in the 
BRET  ratio  observed  between  CXCR4  and 
arrestin2 or 3 (Figs. 8C and D). This suggests that 
phosphorylation of the GRK6 sites either inhibits 
arrestin  binding  to  CXCR4  or  results  in  a 
receptor/arrestin  complex  that  adopts  a 
conformation that is distinct from that promoted 
by  phosphorylation  of  the  extreme  C-terminus.  
Taken  together,  these  results  reveal  that  site-
specific  phosphorylation  of  CXCR4  has  distinct 
effects on not only the recruitment of arrestins but 
also  the  conformation  that  these  proteins  adopt.  
These  processes  work  together  to  dynamically 
modulate CXCR4-mediated signaling. 
 
DISCUSSION 
 
Phosphorylation and arrestin recruitment have 
long  been  appreciated  as  critical  steps  in  the 
process of  GPCR desensitization (9, 10).   More 
recently, a newly appreciated role in initiating G 
protein-independent  signaling  pathways  has 
emerged  for  both  the  GRKs  and  arrestins  (46).  
Studies  using  the  vasopressin  and  angiotensin 
receptors have enabled the elucidation of a model 
where  GRK2/3  negatively  regulate  arrestin-
dependent signaling while GRK5/6 play a positive 
role  in  signaling  (40,  42).    Since  these  initial 
reports,  similar  phenomena  have  been  observed 
for a number of GPCRs, including the β2AR and 
the follicle-stimulating hormone receptor (47, 48), 
suggesting  that  this  model  applies  to  many 
GPCRs.   
Taking into consideration the large diversity 
of  the  GPCR  superfamily,  characterizing  the 
mechanisms involved in receptor regulation under 
“normal”  physiological  conditions  will  add 
significantly  to  our  understanding  of  receptor 
signaling  as  well  as  receptor  dysregulation  in 
disease.    CXCR4  has  emerged  as  a  prominent 
GPCR  due  to  its  reported  role  in  cancer 
progression and metastasis (4) and recent studies 
have provided evidence for the dysregulation of 
CXCR4 in cancer cells (49, 50).  Given the wealth 
of  knowledge  on  the  role  of  CXCR4-mediated 
signaling in cancer (51), it is surprising that the 
regulation  of  CXCR4  function  is  not  better 
understood.  In  this  report,  we  characterize  site-
specific phosphorylation of CXCR4 and provide 
evidence that kinase-specific phosphorylation has 
distinct effects on CXCR4 signaling. 
With  few  exceptions,  the  specific  sites  and 
functional  role  of  GPCR  phosphorylation  are 
largely  unknown.    In  order  to  determine  the 
functional  role  of  site-specific  phosphorylation, 
the sites phosphorylated and the kinases involved 
need  to  be  identified.  Since  mutagenesis  and 
metabolic  labeling  studies  have  suggested  that 
multiple regions of the C terminal tail of CXCR4 
may  be  phosphorylated  (22),  we  used  mass 
spectrometry  and  phospho-specific  antibodies  to 
define  specific  sites  of  phosphorylation.    Using 
these  approaches  we  found  that  CXCL12 
promotes the phosphorylation of 7 serines in the C 
terminal tail (Fig. 2D),  although we  cannot rule 
out the presence of additional sites. We confirmed 
previous studies suggesting that Ser-324 and Ser-
325  are  phosphorylated  (21,  22)  as  well  as  one 
study showing that Ser-339 is phosphorylated (41) 
(Fig. 2C and D).  In addition, we found that Ser-
321  is  phosphorylated,  a  site  that  has  not  been 
previously  implicated  in  CXCR4  regulation.  
Finally,  we  demonstrated  that  Ser-330  is  also 
phosphorylated in response to CXCL12 (Fig. 5A).   
Phospho-specific antibodies have provided a 
powerful  tool  to  enable  characterization  of 
phosphorylation kinetics for a number of GPCRs 
(52-54).    Here,  we  successfully  used  phospho-
specific antibodies against Ser-324/5, Ser-330 and 
Ser-339 and found that phosphorylation at these 
sites occurs with disparate kinetics, peaking at 5-
10 min, ~20 min, and ~2 min following CXCL12 
stimulation, respectively. Based on these results, 
we hypothesize that phosphorylation at these sites 
would  have  distinct  effects  on  desensitization, 
signaling,  and/or  trafficking  following  CXCR4 
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activation.  In this regard, previous studies have 
suggested  that  Ser-324/5  and  Ser-330  play  an 
important role in CXCR4 degradation (23) while 
CXCR4  recycles  to  the  plasma  membrane  with 
varying efficiencies in different cell lines (55-58).  
These  findings  suggest  cell  type  differences  in 
Ser-324/5  or  Ser-330  phosphorylation  may 
regulate  differential  CXCR4  sorting.    These 
phospho-specific antibodies should enable a more 
in-depth  analysis  of  CXCR4  phosphorylation  in 
various tissues and cells.  
To  address  if  site-specific  phosphorylation 
can differentially dictate the regulation of CXCR4 
signaling,  we  evaluated  the  role  of  site-  and 
kinase-specific  phosphorylation  in  CXCR4-
mediated signaling.  We provide novel evidence 
for PKC in selectively phosphorylating Ser-324/5 
following CXCL12 stimulation in HEK293 cells 
and human astroglia (Fig. 3 and supplemental Fig. 
S2A)  with  no  effect  on  Ser-330  or  Ser-339  in 
HEK293 cells (data not shown). Previously, PKC 
has  been  thought  to  be  primarily  involved  in 
heterologous  desensitization  of  CXCR4, 
downstream  of  a  number  of  receptors  (1).  
Interestingly,  Ser-324  and  Ser-325  have  been 
shown to play a prominent role in PKC-mediated 
internalization of CXCR4 (21, 22), although there 
have been conflicting reports for the role of these 
residues  in  CXCL12-mediated  internalization.  
For example, mutation of Ser-324/5 to alanine had 
no effect on internalization in Mv-1-Lu cells (21) 
but  effectively  attenuated  internalization  in 
HEK293 cells (22).  Since Ser-324/5 was robustly 
phosphorylated following CXCL12 stimulation in 
HEK293 cells, cell type dependent differences in 
trafficking  may  be  attributed  to  differences  in 
phosphorylation  or  in  subsequent  protein/protein 
interactions.  Despite this robust phosphorylation, 
PKC  inhibition  had  no  effect  on  CXCR4 
activation of ERK1/2 (data not shown).  Based on 
the  critical  role  of  Ser-324/5  in  receptor 
degradation (23), it is reasonable to hypothesize 
that  PKC-mediated  phosphorylation  drives 
receptor degradation.  In fact, phosphorylation of 
these  residues  is  required  for  the  interaction  of 
AIP4 with CXCR4 and subsequent ubiquitination 
(59).  
We have found that  GRK6  accounts for the 
majority of CXCR4 phosphorylation, contributing 
to  Ser-324/5  phosphorylation  and  being 
principally  responsible  for  Ser-330  and  Ser-339 
phosphorylation (Figs. 4 and 5).  While no GRK-
specific  phosphorylation  motifs  have  been 
identified, GRK2 and 3 prefer acidic residues N 
terminal to the phosphorylation site while GRK5 
and 6 prefer basic residues (10).  Consistent with 
our GRK6 results, there are basic residues located 
N  terminally  to  Ser-324/5,  Ser-330  and  Ser-339 
(Fig. 2D).  Previous studies have shown that the 
deletion of GRK6 in a mouse had marked effects 
on  the  activity  of  CXCR4,  leading  to  enhanced 
function  and  a  lack  of  desensitization  (27,  28).  
Surprisingly, loss of GRK6 had different effects 
on  CXCL12-mediated  chemotaxis  in  neutrophils 
and  T  cells,  suggesting  that  the  regulation  of 
CXCR4 function by phosphorylation may be cell 
type  dependent  (27,  28).    While  these  previous 
studies did not evaluate signaling, our work has 
shown that loss of GRK6 significantly increased 
calcium  mobilization  while  reducing  ERK1/2 
activation.    Finally,  mutation  of  the  identified 
GRK6 phosphorylation sites to alanine resulted in 
an apparent increase in arrestin recruitment (Fig. 
8C and D).  However, as BRET is dependent on 
the proximity of the donor and acceptor tags (60) 
and there was no change in the timing of arrestin 
recruitment  (Fig.  8),  we  propose  that  loss  of 
GRK6 phosphorylation results in arrestin2 and 3 
adopting  a  conformation  that  is  unable  to 
effectively serve as a platform for ERK activation. 
Two  residues  at  the  extreme  C  terminus  of 
CXCR4 (one between Ser-346-348 and either Ser-
351  or  Ser-352)  are  also  phosphorylated  in 
response  to  CXCL12  stimulation  (Fig.  2D).  
Based on the acidotropic nature of these serines, 
we  postulate  that  these  residues  are 
phosphorylated by GRK2 and/or GRK3 (Fig. 2D).  
While we were unable to directly test this in our 
system,  recent  studies  suggest  that  GRK3 
phosphorylates  the  far  C-terminal  region  of 
CXCR4  (26).  Using  fibroblasts  or  leukocytes 
derived  from  patients  with  WHIM  syndrome, 
Balabanian  et  al.  showed  that  only  over-
expression of GRK3 enhanced internalization of 
wild  type  CXCR4  but  not  a  C-terminally 
truncated CXCR4 lacking the last 15 amino acids 
(which  contains 10 serines and threonines).  By 
comparison,  McCormick  et  al.  recently  showed 
that a CXCR4 mutant lacking the last 19 amino 
acids  is  defective  in  GRK6  and  arrestin3 
recruitment compared to WT CXCR4 while there 
was no  affect on  GRK3 or arrestin2 association 
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(61). However, knock down of GRK3 or GRK6 
affected the trafficking of WT and mutant CXCR4 
to  a  similar  extent  (61),  suggesting  that  both 
kinases regulate CXCR4 function.  Since previous 
work  has  demonstrated  that  Ser-338  is  not 
phosphorylated in response to CXCL12 (41) and 
we have shown that Ser-339 is phosphorylated by 
GRK6  (Fig.  5C),  the  effects  observed  by 
Balabanian et al. (26) and McCormick et al. (61) 
could  be  explained  by  GRK3-mediated 
phosphorylation of the far C-terminal residues in 
response to CXCL12 stimulation, although none 
of  these  studies  exclude  a  potential  role  for 
GRK2.  Interestingly, knock down of GRK3 had 
no effect on calcium mobilization but significantly 
decreased  ERK1/2  activation  (Fig.  6  and 
supplemental Fig.  S3).  Mutation of the last five 
serine residues to alanine decreased, but did not 
eliminate,  arrestin3  recruitment  to  CXCR4 
suggesting  this  was  sufficient  for  receptor 
desensitization.    However,  GRK3-mediated 
phosphorylation of C-terminal residues may act in 
concert with GRK6-mediated phosphorylation to 
participate in ERK1/2 activation through altering 
the conformation of activated arrestin (Fig. 8).  
Interestingly, we found that GRK2 negatively 
regulates  CXCR4-mediated  activation  of  both 
calcium  flux  and  ERK1/2  (Fig.  6  and 
supplemental Fig. S3).  Previous over-expression 
studies  showed  that  GRK2  enhances  CXCR4 
internalization  (22,  24)  and  negatively  regulates 
CXCL12-mediated  ERK  activation  downstream 
of the receptor in HEK293 cells, possibly through 
interaction with MEK (25). Thus, we envision that 
GRK2-mediated phosphorylation likely promotes 
arrestin3 binding to CXCR4 and inhibits calcium 
signaling  while  GRK2  inhibition  of  ERK  may 
occur  via  interaction  with  MEK  as  previously 
shown (25).  
The  positive  role  of  GRK3  and  GRK6  on 
ERK1/2  activation  prompted  us  to  evaluate  the 
role of arrestins in CXCR4 signaling.   Previous 
studies have suggested that arrestin3 is involved 
in  desensitization,  internalization,  and  activation 
of  p38  and  ERK1/2  (22,  24,  27,  62)  whereas 
arrestin2  is  involved  in  sorting  CXCR4  to  the 
lysosomes for degradation (63). Similar to studies 
on the angiotensin and vasopressin receptors (37, 
64), we found that arrestin2 and 3 have different 
effects on CXCR4 signaling.  Our results suggest 
that arrestin3 plays a primary role in desensitizing 
G  protein  activation  (i.e.,  inhibiting  calcium 
mobilization),  a  pathway  that  appears  partially 
dependent on GRK2 and GRK6 phosphorylation 
of CXCR4.  Conversely, arrestin2 plays a positive 
role in ERK1/2 activation and appears to require 
phosphorylation  of  the  receptor  by  both  GRK3 
and  GRK6.    This  pattern  of  arrestin-mediated 
activation  of  ERK1/2  is  somewhat  unique  since 
most GPCRs either require both arrestins (12) or 
arrestin3  (40,  64)  for  ERK  activation  although 
there is one report that PAR1 selectively utilizes 
arrestin2 (65).  This is the first demonstration that 
GRK2/3  and  GRK5/6  cooperate  in  terms  of 
signaling.  
  In  summary,  our  results  support  a  model 
where  GRK2  and  GRK6-mediated 
phosphorylation leads to recruitment of arrestin3 
(Fig. 9B).  This serves to uncouple CXCR4 from 
activation  of  Gi  thereby  regulating  calcium 
release.  In addition, GRK3- and GRK6-mediated 
phosphorylation of CXCR4 promotes interaction 
with  arrestin2  and  results  in  full  activation  of 
ERK1/2  (Fig.  9C).    These  results  provide  a 
foundation  to  better  understand  how  CXCR4  is 
regulated  and  identify  distinct  regulatory 
molecules  that  can  be  targeted  to  modulate 
CXCR4 signaling in disease.  
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FIGURE LEGENDS 
 
Figure 1.  Establishing and characterizing HEK293 cells that stably express CXCR4.  A) HEK293 
cells  or  cells  stably  expressing  Flag  CXCR4  (Flag  CXCR4  cells)  were  loaded  with  the  ratiometric 
calcium indicator Fura-2/AM prior to stimulation with CXCL12 (100 nM).  The change in intracellular 
calcium  was  calculated  by  monitoring  the  change  in  fluorescence  of  Fura-2/AM.    Shown  is  a 
representative trace of calcium mobilization from three independent experiments.  B) Following a 6 hr 
serum  starvation,  HEK293  cells  or  Flag  CXCR4  cells  were  stimulated  with  CXCL12  for  the  times 
indicated.  pERK2 was normalized to total ERK2 by LiCor imaging to determine that overexpression of 
CXCR4 led to a 2.5 fold-increase in ERK activation.  Shown are representative Western blots of phospho-
ERK1/2  and  total  ERK2  from  three  independent  experiments.  CXCL12-promoted  retardation  of 
electrophoretic mobility of endogenous CXCR4 (C) or Flag tagged CXCR4 (D).  Following a 6 hr serum 
starvation, cells were stimulated with 100 nM CXCL12 for the indicated time.  Crude membranes were 
prepared  and  50  µg  of  solubilized  protein  (endogenous)  or  equal  volume  of  whole  cell  lysate  (Flag 
CXCR4)  was  separated  by  10%  SDS-PAGE.    Shown  is  a  representative  Western  blot  from  four 
independent experiments.   
 
Figure 2.  Purification and mass spectrometry analysis of CXCR4.  A) Flag CXCR4 was purified 
from five 15-cm plates following a 10 min stimulation with 50 nM CXCL12.  The bulk of the receptor 
(~80%) elutes in fractions 2 and 3 and is highly purified as shown by Coomassie blue staining (B).  C) 
Shown is a representative mass spectrum of the peptide Thr-318 to Leu-328 following a chymotrypsin 
digest demonstrating that CXCR4 is phosphorylated on Ser-324 and Ser-325. D) Amino acid sequence of 
the  C  terminal  tail  of  CXCR4.    Residues  highlighted  in  red  are  those  that  are  predicted  to  be 
phosphorylated  by  mass  spectrometry.    Brackets  under  Ser-338-Ser-341,  Ser-346-Ser-348,  and  Ser-
351/Ser-352 indicate that one residue in each cluster is phosphorylated, though the exact residue was not 
identified by mass spectrometry. 
 
Figure 3.  Characterization of anti-pSer-324/5 (pS324/5).  A) Shown is a representative Western blot 
demonstrating the specificity of the pS324/5 antibody.  Ten µg of purified antibody was incubated for 10 
min with vehicle (PBS), 10 µg of peptide (C-Ahx-RGSSLKIL) or 10 µg of phospho-peptide (C-Ahx-
RG(pS)(pS)LKIL) prior to overnight incubation with the nitrocellulose blots.  B) Cells stably expressing 
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Flag CXCR4 were stimulated at the time points indicated with 100 nM CXCL12.  Lysates were processed 
and separated to visualize the agonist promoted gel shift of CXCR4.  Blots were incubated overnight with 
1:1000  dilution  of  crude  pS324/5  antibody.    pS324/5  was  normalized  to  total  CXCR4  and  data  is 
presented  as  fold  increase  over  basal  (±  S.E.M.,  n=4).    The  fold  increase  at  10  min  is  significantly 
different from 2, 30, and 60 min (p=0.004, 0.05, and 0.009, respectively) but not 5 min.  C) Cells stably 
expressing Flag CXCR4 were treated overnight with vehicle (PBS) or pertussis toxin (100 ng/ml) prior to 
stimulation with 100 nM CXCL12. pS324/5 was normalized to total CXCR4 and data is presented as 
percent maximum of vehicle treated cells  (± S.E.M., n=3). D) Cells stably expressing Flag CXCR4 were 
serum starved for 6 hr.  30 min prior to CXCL12 stimulation, cells were pretreated with 2.5 µM Bis I or 
Bis V.  pS324/5 was normalized to total CXCR4 and data is presented as fold increase over basal (Bis V) 
(± S.E.M., n=4; *p≤0.05, **p≤0.01, ***p≤0.001). 
 
Figure  4.    GRK6  contributes  to  Ser-324/5  phosphorylation  following  CXCL12  stimulation.    A) 
Representative Western blot demonstrating specific and efficient knock down of GRKs endogenously 
expressed in HEK293 cells 72 hr post-transfection. B) Knock down of GRK6, but not GRK2, GRK3 or 
GRK5 led to a significant reduction in phosphorylation of Ser-324/5.  Left panel: representative Western 
blot using purified anti-pS324/5.  Right panel: comparison of pS324/5 phosphorylation following a 5 min 
stimulation with CXCL12.  pS324/5 was normalized to total CXCR4 and data is presented as percent of 
control at 5 min (± S.E.M., n=4).  C) GRK6 knock down and PKC inhibition almost completely abolished 
phosphorylation of Ser-324/5.  Cells transfected with GRK6 siRNA were pretreated with 2.5 µM Bis I or 
Bis V 30 min prior to stimulation with CXCL12.  Left panel:  representative Western blot using purified 
anti-pS324/5.    Right  panel:    pS324/5  was  normalized  to  total  CXCR4  and  data  is  presented  as  fold 
increase over basal in control/Bis V treated cells (± S.E.M., n=3; *p≤0.05, **p≤0.01, ***p≤0.001). 
 
Figure 5.  Ser-330 and Ser-339 in CXCR4 are phosphorylated by GRK6.  A) Cells expressing Flag 
CXCR4 were serum starved for 6 hr prior to stimulation with 100 nM CXCL12 for times indicated.  An 
equal volume of lysate was separated by SDS-PAGE and blotted with purified anti-pS330 (top left panel) 
or anti-pS339 (bottom left panel).  pS330 blots were processed in order to visualize the gel shift of 
CXCR4.     Right panel:  pS330 or pS339 blotting was normalized to total CXCR4 and data presented as 
fold increase over basal (± S.E.M., n=4).  For Ser330, the fold increase at 20 min is significantly different 
from 5, 10 and 60 min (p=0.01, 0.02, and 0.004, respectively) but not 30 min.  For Ser339, the fold 
increase at 2 min is significantly different from 5, 10 and 30 min (p=0.01, 0.01, and 0.02, respectively).  
Seventy-two hr post-transfection, an equal volume of cell lysate was separated to visualize the gel shift of 
CXCR4 and blotted using purified anti-pS330 (B) or anti-pS339 (C).  Shown are representative Western 
blots of four separate experiments.   
 
Figure 6.  GRKs differentially regulate signaling  following activation of endogenous  CXCR4 in 
HEK293 cells.  A) HEK293 cells were loaded with the ratiometric calcium indicator Fura-2A/M 72 hr 
after siRNA transfection.   Cells  were stimulated  with 100 nM  CXCL12  and changes in intracellular 
calcium were calculated from changes in fluorescence.  Left panel: shown is a representative trace from 
six separate experiments.  Right panel: mean (± S.E.M.) increase in peak calcium transient calculated 
from  six  separate  experiments.    B)  Effect  of  GRK  knock  down  on  CXCL12-mediated  activation  of 
ERK1/2.  Seventy-two hr post-transfection, cells were serum starved for 6 hr prior to stimulation with 
CXCL12 (100 nM).  Shown is a representative Western blot from five independent experiments. C) Left 
panel: pERK2 was normalized to total ERK2 and data are presented as percent maximal ERK2 activation 
as compared to control (± S.E.M., n=4). Right panel: comparison of maximal ERK2 activation (5 min) 
following stimulation with CXCL12 (100 nM) (± S.E.M., n=4; *p≤0.05, **p≤0.01, ***p≤0.001). 
 
Figure 7.  Non-visual arrestins differentially regulate CXCR4-mediated signaling.  A) Mean (± S.E.M.) 
increase in peak calcium transient following stimulation of endogenous CXCR4 calculated from seven 
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separate experiments.  B) Mean (± S.E.M.) increase in peak calcium transient following stimulation of 
Flag CXCR4 calculated from three separate experiments.  C and D) Effect of arrestin knock down on 
ERK1/2 activation following activation of HEK293 (C) or Flag CXCR4 (D) cells. Seventy-two hr post-
transfection, cells were serum starved for 6 hr prior to stimulation with CXCL12 (100 nM).  Left panels: 
shown are representative Western blots from seven (C) and four (D) separate experiments.  Right panels: 
pERK2 was normalized to total ERK2 and data is presented as percent maximal ERK2 activation as 
compared to control (± S.E.M.; *p≤0.05, **p≤0.01, ***p≤0.001). 
 
Figure 8. Phosphorylation of CXCR4 differentially regulates the recruitment and conformation of the 
non-visual arrestins.  A BRET assay was performed to determine if CXCR4 was able to recruit the non-
visual arrestins following activation.  HEK-293T cells were transiently transfected with wild type (WT) 
RlucII-tagged CXCR4 and either GFP-tagged arrestin2 or arrestin3.  CXCL12-stimulation results in the 
recruitment of both arrestin2 (A) and arrestin3 (B).  Interestingly, alanine substitution of the proposed 
GRK2/3  sites  (5A  Tail)  eliminates  arrestin2  recruitment  (C)  and  significantly  decreases  arrestin3 
recruitment (D).  In contrast, alanine substitution of the identified GRK6 sites (GRK6SA) results in an 
increase in the BRET ratio observed, suggesting an altered conformation of the arrestins (C and D). 
 
Figure 9. Regulation of CXCR4 activity and signaling. A) Upon ligand binding, CXCR4 activates a 
number of signaling cascades resulting in calcium release from intracellular stores and phosphorylation of 
ERK1/2.   B) Phosphorylation of CXCR4 by GRK6 (Ser324/5, Ser330, and Ser339) and GRK2 (residues 
between Ser-346 and Ser-352) results in the recruitment of arrestin3 to CXCR4, thereby attenuating G 
protein activation and calcium release.  C) Phosphorylation of CXCR4 by GRK6 (Ser324/5, Ser330, and 
Ser339) and GRK3 (residues between Ser-346 and Ser-352) results in a conformation of arrestin2 that 
allows  for  full  activation  of  ERK1/2.    In  contrast,  GRK2  inhibits  ERK1/2  activation  most  likely  by 
regulating the activity of MEK (25). 
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Table 1 
Lys-C Digestion 
Peptide    Predicted m/z Ratio  Observed m/z Ratio 
311TSAQHALTSVSRGSSLK
326    1730  1730 
311TSAQHALTSVSRGSS*LK
326    1730  1810 
311TSAQHALTSVSRGS*S*LK
326    1730  1890 
311TSAQHALTSVS*RGSSLK
326    1730  1810 
311TSAQHALTSVS*RGSS*LK
326    1730  1890 
334RGGHSSVSTESESSSFHSS
352    1952  1951 
334RGGHSSVSTESESSSFH[SS]
352    1952  2031 
334RGGHSSVSTESE[SSS]FHSS
352    1952  2031 
334RGGH[SSVS]TESESSSFHSS
352    1952  2031 
Chymotrypsin Digestion 
Peptide    Predicted m/z Ratio  Observed m/z Ratio 
316ALTSVSRGSSLKIL
328    1432  1432 
316ALTSVSRGSS*LKIL
328    1432  1511 
316ALTSVSRGS*S*LKIL
328    1432  1591 
316ALTSVSRGSSL
326    1077  1077 
316ALTSVSRGSS*L
326    1077  1157 
318TSVSRGSSLKIL
328    1248  1248 
318TSVSRGS*S*LKIL
328    1248  1408 
310KTSAQHALTSVSRGSSLKIL
328    2084  Not observed 
310KTSAQHALTSVSRGS*S*LKIL
328    2084  2244 
 
*  Denotes phosphorylated residues as predicted by LC/MS/MS 
[ ]   Denotes one of the highlighted residues is phosphorylated as predicted by LC/MS/MS  
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